TITLE

Semantics, Sullied Science, and the Federal Drug Administration

AUTHOR(S)
WHITAKER, LEIGHTON C.
PUB. DATE
March 2009
SOURCE
Ethical Human Psychology & Psychiatry;2009, Vol. 11 Issue 1, p3
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The author reflects on several issues related to psychiatry. He notes the value of disease premise ideology in psychiatric drug studies. He discusses the role of semantics in psychiatry, citing that semantics may short-circuit critical thinking. He points out the failure of the U.S. Food and Drug Administration (FDA) to protect citizens from commercial exploitation of their emotional vulnerabilities and the need for the FDA to be more attentive to and honoring of genuine science.
ACCESSION #
38123724

 

Related Articles

  • Current Drug Information.  // Annals of Internal Medicine;Aug70, Vol. 73 Issue 2, p291 

    Provides information on the drug applications for lithium carbonate approved by the U.S. Food and Drug Administration. History of lithium in psychiatry; Indication for the use of lithium carbonate; Toxic reactions related to serum lithium levels.

  • Generalizabilidad o validez externa de los ensayos clínicos en psiquiatría. Okuda, Mayumi; Blanco, Carlos // Revista Colombiana de Psiquiatria;Mar2010 Supplement, p143S 

    Introduction: To approve the prescription of a medication in the United States, the Food and Drug Agency (Food and Drug Administration (FDA)) requires at least two Phase III clinical trials demonstrate the safety and efficacy of the medication. In these studies, however, the results can be...

  • Panel calls for new 'black box' warning.  // Counseling Today;Jan2007, Vol. 49 Issue 7, p3 

    The article reports on the extension given by Psychopharmacologic Drug Advisory Committee of the U.S. Food and Drug Administration (FDA) on the existing pediatric warning label on antidepressant drugs. The committee recommends the suicide-risk warning labels be extended to include adults up to...

  • Budgets & Belt Tightening. Auerbach, Michael // Pharmaceutical Processing;Feb2010, Vol. 25 Issue 2, p6 

    The author reflects on the request of the U.S. Food and Drug Administration to raise an amount of 4.03 billion dollars as part of the 2011 budget for the protection and promotion of public health. He comments that the amount is large and they pale in comparison to the latest announcement of the...

  • Issues related to risk evaluation and mitigation strategies in health-system pharmacy. Coffey, Justine // American Journal of Health-System Pharmacy;9/15/2010, Vol. 67 Issue 18, p1512 

    The article presents the author's views on the issues focusing on the risk evaluation and mitigation strategies (REMSs) in health-system pharmacy. He is of the opinion that patient access to some medications could be compromised if the pharmacy's input and involvement in the development of REMSs...

  • FDA Makes New Plans About Conflict of Interest. Levin, Arthur A. // HealthFacts;Apr2007, Vol. 32 Issue 4, p4 

    The author offers reflections on the plan of the U.S. Food and Drug Administration (FDA) to revamp its rules in selecting medical experts and scientists to serve on its drug and device advisory committees. He addresses the key role of advisory committees in advising the FDA concerning the...

  • Pharmaceutical Industry to Public: Drop Dead. Napoli, Maryann // HealthFacts;May2008, Vol. 33 Issue 5, p2 

    The author ponders the crimes committed by the pharmaceutical industry in the U.S. She presents a scenario which illustrates the litigation process faced by a pharmaceutical company. She believes its absurd to presume that the Food and Drug Administration (FDA) approval process guarantees...

  • Lack of Labeling Requirement Makes Cloned Food a Concern. Enis, Matthew // SN: Supermarket News;1/21/2008, Vol. 56 Issue 3, p12 

    The author discusses the lack of labeling requirement for cloned food in the U.S. He reveals that artificially cloned animals were approved for consumption, no label required, by the U.S. Food & Drug Administration (FDA). He argues that the volume of product recalls and contamination scares in...

  • Out with the new, in with the old. Garber, Alan J. // Endocrine Today;Jan2012, Vol. 10 Issue 1, p7 

    The author reflects on a continuation of trends toward increasing emphasis on drug safety by the U.S. Food and Drug Administration (FDA) in which the potential for much more frequent untoward events for agents under review is being overlooked.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics